Company Successfully Completes Phase 2a Clinical Trial Fourth Quarter or Full Year Highlights • Appointed Douglas Johnston as CFO in November 2022 • Successfully completed Initial Public Offering, attained NASDAQ CM listing • Year-end cash balance in excess of $5 million Subsequent Events…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.